Ozmosi | Epoetin zeta Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Epoetin zeta

Alternative Names: epoetin zeta
Clinical Status: Inactive
Latest Update: 2023-05-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: EPO Agonist

Novel Mechanism: Yes

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Croatia | Cyprus | Estonia | France | Germany | Hungary | Malaysia | Norway | Portugal | Spain | Turkey | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: STADA R&D
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Preleukemia|Myelodysplastic Syndrome

Phase 3: Kidney Diseases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2007-002984-28

 Epoetin STADA s.c. vs. Erypo® s.c. as maintenance treatment of renal anemia

P3

Completed

Kidney Diseases

2010-04-19

2022-03-12

Treatments

NCT03598582

 RETA

P4

Completed

Myelodysplastic Syndrome|Preleukemia

2017-05-01

2019-03-22

Treatments

Recent News Events

Date

Type

Title

05/01/2023

PubMed

 Three-year safety observation of subcutaneous administration of epoetin-zeta in patients with chronic renal anemia: Results from PASCO II study.

02/01/2023

PubMed

 Data from a microdosed recombinant human erythropoietin administration study applying the new biotinylated clone AE7A5 antibody and a further optimized sarcosyl polyacrylamide gel electrophoresis protocol.

08/10/2022

News Article

 The Global Chemotherapy Induced Anemia Drug Market grew USD 1,266.71 million by 2027, at a CAGR of 9.78%.

06/09/2022

News Article

 STADA and Alvotech broaden European patients' options by launching Hukyndra® high-concentration, citrate-free adalimumab

07/21/2021

News Article

 Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe

02/11/2021

News Article

 Insights on the Erythropoietin (EPO) Global Market to 2030 - Identify Growth Segments for Investment

06/01/2020

PubMed

 Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions